# A Study of Lorigerlimab in Participants With Advanced Solid Tumors

> **NCT06730347** · PHASE2 · RECRUITING · sponsor: **MacroGenics** · enrollment: 60 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Clear Cell Adenocarcinoma of Ovary
- Clear Cell Adenocarcinoma of Vulva
- Clear Cell Adenocarcinoma of Vagina
- Clear Cell Adenocarcinoma of Cervix
- Clear Cell Adenocarcinoma of Uterus
- Clear Cell Adenocarcinoma of Fallopian Tube
- Clear Cell Adenocarcinoma of Peritoneum
- Endometrial Cancer

## Interventions

- **BIOLOGICAL:** Lorigerlimab

## Key facts

- **NCT ID:** NCT06730347
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-02
- **Final completion:** 2027-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06730347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06730347, "A Study of Lorigerlimab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06730347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*